Patient selection for hemiablative focal therapy of prostate cancer: Variables predictive of tumor unilaterality based upon radical prostatectomy

Cancer

Volumn 115, Issue 10, 2009, Pages 2104-2110

  Polascik, Thomas J ^a   Mayes, Janice M ^a   Schroeck, Florian R ^a   Sun, Leon ^a   Madden, John F ^a   Moul, Judd W ^a   Mouraviev, Vladimir ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Cryosurgery; Hemiablation; Patient selection; Prostatic neoplasms; Tumor unilaterality

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER RISK; CANCER STAGING; COMMUNITY HOSPITAL; FALSE NEGATIVE RESULT; FALSE POSITIVE RESULT; GLEASON SCORE; HEMIABLATIVE FOCAL THERAPY; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PATIENT SELECTION; PREDICTIVE VALIDITY; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATE SURGERY; PROSTATECTOMY; RISK FACTOR; SENSITIVITY AND SPECIFICITY;

ABLATION TECHNIQUES; BIOPSY; FAMILY HEALTH; HUMANS; MALE; PATIENT SELECTION; PROSTATECTOMY; PROSTATIC NEOPLASMS;

EID: 61349202058     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.24258     Document Type: Article

References (20)

1. Polascik TJ, Mayes JM, Sun L, Madden JF, Moul JW, Mouraviev V. Pathologic stage t2a and t2b prostate cancer in the recent prostate-specific antigen era: implications for unilateral ablative therapy. Prostate. 2008;68:1380-1386.
2. Lambert EH, Bolte K, Masson P, Katz AE. Focal cryosurgery: encouraging health outcomes for unifocal prostate cancer. Urology. 2007;69:1117-11220.
3. Cooperberg MR, Lubeck DP, Meng MV, Mehta SS, Carroll PR. The changing face of low-risk prostate cancer: trends in clinical presentation and primary management. J Clin Oncol. 2004;22:2141-2149.
4. Onik G, Vaughan D, Lotenfoe R, Dineen M, Brady J. "Male lumpectomy": focal therapy for prostate cancer using cryoablation. Urology. 2007;70(suppl):16-21.
5. Ellis DS, Manny TB Jr, Rewcastle JC. Focal cryosurgery followed by penile rehabilitation as primary treatment for localized prostate cancer: initial results. Urology. 2007;70(suppl):9-15.
6. Ohori M, Eastham JA, Koh H, Kurolwa. K, Slawin. K, Wheeler. TM, et al. PT: is focal therapy reasonable in patients with early stage prostate cancer (cap)- an analysis of radical prostatectomy (rp) specimens. Paper presented at the AUA Annual Meeting: May 20-25, 2006; Atlanta, Ga. (Abstract 1574).
7. Cheng L, Jones TD, Pan CX, Barbarin A, Eble JN, Koch MO. Anatomic distribution and pathologic characterization of small-volume prostate cancer (<0.5 ml) in whole-mount prostatectomy specimens. Mod Pathol. 2005;18:1022-1026.
8. Arora R, Koch MO, Eble JN, Ulbright TM, Li L, Cheng L. Heterogeneity of Gleason grade in multifocal adenocarcinoma of the prostate. Cancer. 2004;100:2362-2366.
9. Mouraviev V, Mayes JM, Sun L, Madden JF, Moul JW, Polascik TJ. Prostate cancer laterality as a rationale of focal ablative therapy for the treatment of clinically localized prostate cancer. Cancer. 2007;110:906-910.
10. Bahn DK, Silverman P, Lee F Sr, Badalament R, Bahn ED, Rewcastle JC. Focal prostate cryoablation: initial results show cancer control and potency preservation. J Endourol. 2006;20:688-692.
11. D'Amico AV, Moul J, Carroll PR, Sun L, Lubeck D, Chen MH. Cancer-specific mortality after surgery or radiation for patients with clinically localized prostate cancer managed during the prostate-specific antigen era. J Clin Oncol. 2003;21:2163-2172.
12. Onik G. Rationale for a "Male lumpectomy," A prostate cancer targeted approach using cryoablation: results in 21 patients with at least 2 years of follow-up. Cardiovasc Intervent Radiol. 2008;31:98-106.
13. Partin AW, Mangold LA, Lamm DM, Walsh PC, Epstein JI, Pearson JD. Contemporary update of prostate cancer staging nomograms (partin tables) for the new millennium. Urology. 2001;58:843-848.
14. Weight CJ, Reuther AM, Gunn PW, Zippe CR, Dhar NB, Klein EA. Limited pelvic lymph node dissection does not improve biochemical relapse-free survival at 10 years after radical prostatectomy in patients with low-risk prostate cancer. Urology. 2008;71:141-145.
15. Smith JA Jr. Radical prostatectomy for low risk carcinoma of the prostate. World J Urol. 2008;26:443-446.
16. Presti JC. Prostate biopsy: current status and limitations. Rev Urol. 2007;9:93-98.
17. Mayes J, Mouraviev V, Sun L, Tsivian M, Madden J, Polascik T. Can the conventional sextant prostate biopsy accurately predict unilateral prostate cancer in low-risk, localized, prostate cancer? Urol Oncol. In press.
18. Barber T, Pansare V, Nikolavsky D, Pontes E, Sakr W, Cher M. Pathologic characteristics of contralateral prostate cancer in low-risk, localized, prostate cancer? Urol Oncol. In press.
19. Wei JT. Prostate biopsies: how well do they predict tumor location? Urol Times. 2006;34:32-33.
20. Barzell WE, Melamed MR. Appropriate patient selection in the focal treatment of prostate cancer: the role of transperineal 3-dimensional pathologic mapping of the prostate-a 4-year experience. Urology. 2007;70(suppl):27-35.